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1. Introduction 
Diabetes is a metabolic disorder characterised by chronic hyperglycaemia, hypertension, 
dyslipidaemia, microalbuminuria and inflammation. Moreover, there are a number of 
vascular complications associated with this condition including retinopathy, neuropathy 
and nephropathy. Diabetic nephropathy is the major cause of end-stage renal disease in 
Western societies affecting a substantial proportion (25-40%) of patients with diabetes. 
Diabetic nephropathy is defined as a progressive decline in glomerular filtration rate, 
accompanied by proteinuria and other end-organ complications such as retinopathy. 
It is widely accepted, that diabetic nephropathy is the product of hemodynamic and 
metabolic factors which act in concert and drive its development and progression. Metabolic 
factors include hyperglycaemia, hyperlipidaemia and advanced glycation. Hemodynamic 
factors include alterations in flow and pressure and the activation of the Renin-Angiotensin 
system (RAS). Together, the hemodynamic and metabolic factors activate common 
downstream signalling pathways, which potentiate the activation of target growth factors 
and signalling pathways which likely drive the development of DN. At present the most 
effective therapeutics for the treatment of DN target the renin-angiotensin system. 
Unfortunately, whilst they slow down the progression of DN they do not prevent it and 
thus novel therapeutics and potential targets required.  
In recent times the downstream intracellular signalling pathways and their modulators have 
been central focus for the investigation of novel therapeutic targets for the treatment of DN. 
These targets include advanced glycation end products (AGEs) and their receptors, glucose 
transport molecules, NFB, ROS, PKC, inflammatory molecules, including adipokines, 
chemokines, adhesion molecules and pro-inflammatory cytokines. Moreover, pro-fibrotic 
molecules , including EGF, VEGF, CTGF and arguably the most important, TGF-ǃ, which 
are known to potentiate the morphological alterations associated with DN have also been 
targeted.  Recently, epigenetic alterations, including histone, DNA methylation, metabolic 
memory and microRNA’s have demonstrated their potential as novel therapeutic targets in 
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the area of DN. Importantly a number of these potential therapies are the focus of clinical 
trials or are in pre-clinical investigations.  
In summary this chapter will investigate the hemodynamic, metabolic and epigenetic factors 
which drive the development of diabetic nephropathy and their subsequent downstream 
signalling pathways. Importantly, we will discuss the limitations of current therapeutic 
strategies and development of novel therapeutic targets which are presently in either pre-
clinical experimental investigations or clinical trials. 
2. Diabetes 
Today, it is estimated that approximately 180 million individuals worldwide have diabetes 
and WHO predicts that this is likely to double by the year 2030. The incidence of diabetes is 
increasing across the board, irrespective of age, sex or ethnicity (Sowers and Stump 2004). 
Diabetes is a metabolic disorder characterised by chronic hyperglycaemia, and often co-
morbidities such as hypertension, dyslipidaemia and inflammation, with the major types 
being type 1 (insulin-dependant) or type 2 (commonly non-insulin dependant) (Sowers and 
Stump 2004; O'Connor and Schelling 2005). Both forms of diabetes are associated with 
micro- and macrovascular complications which include retinopathy, neuropathy, 
cardio/cerebrovascular disease and nephropathy which are the major cause of mortality 
and morbidity in diabetic patients (Cooper, Gilbert et al. 1998; Giacchetti, Sechi et al. 2005).   
3. Diabetic nephropathy 
Diabetic nephropathy is defined as a progressive decline in glomerular filtration rate, 
accompanied by proteinuria and other end-organ complications such as retinopathy 
(O'Connor and Schelling 2005). Diabetic nephropathy progresses to end-stage renal disease 
via a number of stages including normoalbuminuria, microalbuminuria/incipient diabetic 
nephropathy, macroalbuminuria and finally end-stage renal disease (Giacchetti, Sechi et al. 
2005; O'Connor and Schelling 2005). Progression to end stage renal disease is enhanced by 
hyperglycaemia, hypertension and proteinuria, which are all common in diabetes (Cooper 
1998; Mene, Festuccia et al. 2001; Marshall 2004; Wolf 2004). 
Renal disease in diabetic patients is characterised by hemodynamic (hyperfiltration and 
hyperperfusion) as well as structural abnormalities (glomerulosclerosis, alterations in 
tubulointerstitium including interstitial fibrosis) and metabolic changes (Cooper 2001). More 
importantly, it appears that all renal cell types are affected by hyperglycaemic injury 
including glomerular podocytes, mesangial and endothelial cells, tubular epithelial cells, 
interstial fibroblasts, and vascular endothelia (Kanwar, Wada et al. 2008). Within glomeruli, 
there is thickening of basement membranes, mesangial expansion and hypertrophy and 
glomerular epithelial cell (podocyte) loss (Bohlender, Franke et al. 2005). In conjunction, 
disease progression is also seen in the tubulointerstitial compartment causing expansion of 
tubular basement membranes, tubular atrophy, interstitial fibrosis and arteriosclerosis 
(Marshall 2004).   
To date, the most effective clinical treatments to prevent the progression of diabetic 
nephropathy are strict blood glucose control and anti-hypertensives (1998; 2002; 2003). 
Unfortunately, present therapies have failed to prevent new cases of diabetic nephropathy 
and progression as such novel therapeutic approaches are required. It is widely accepted 
that there metabolic, hemodynamic and genetic components of diabetic nephropathy. Novel 
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therapeutics which are either in pre-clinical or clinical investigations target these factors in 
the hope of achieving the ultimate goal, prevention of diabetic nephropathy.  
4. Potential therpeutic targets and approaches  
4.1 Modulating hemodynamic pathways  
Hyperfiltration, which presents as a marked increase in glomerular filtration rate, is widely 
recognised as being an early marker of diabetic nephropathy (Kanwar, Sun et al.; Anderson 
and Brenner 1988).  Elevations in intra-renal pressure or glomerular capillary pressure are 
thought to induce the development of hyperfiltration thus highlighting the importance of 
the hemodynamic pathways in DN. Furthermore, the UK prospective diabetes study in type 
2 diabetic patients, highlights the importance of hemodynamic influences in the 
development of DN. Diabetic subjects randomised to receive tighter blood pressure control, 
exhibited a concomitant reduction in microalbuminuria and clinical proteinuria (1998) To 
date the most effective treatments for both type 1 and type 2 diabetic patients to retard the 
progression of diabetic complications, are anti-hypertensives which target the renin-
angiotensin system (Lewis, Hunsicker et al. 1993; Brenner, Cooper et al. 2001).  
4.2 The Renin-Angiotensin System (RAS) 
The renin-angiotensin system (RAS) is a co-ordinated hormonal cascade, which modulates 
vasoconstriction and facilitates renal-sodium absorption to maintain blood pressure control. 
The RAS cascade is initiated by the production of renin, which is released from renal 
juxtaglomerular cells, and converts angiotensinogen to angiotensin I. Angiotensin I, an 
inactive hormone, is subsequently cleaved into Angiotensin II by angiotensin converting 
enzyme (ACE). Angiotensin II drives the RAS and elicits its effects by binding to cellular 
receptors, the Angiotensin II type I receptor (AT1) or angiotensin type 2 receptor type II 
(AT2). It was originally postulated that AT1 was the primary receptor and modulator of the 
actions of Ang II, however in recent years it has been widely accepted that AT1 and AT2 
elicit opposing actions upon ligand interaction with Ang II.  The RAS is known to exist both 
systemically and locally in a number of different organs throughout the body including 
kidney, and vasculature (Wiecek, Chudek et al. 2003; Wolf 2004). Activation of the local 
renal RAS appears to be independent of the systemic RAS. In diabetes, the local RAS has 
been found to be up-regulated, in particular within the kidney, whilst the systemic RAS 
appears to be down-regulated (Gilbert, Krum et al. 2003; Wiecek, Chudek et al. 2003; 
Schrijvers, De Vriese et al. 2004; Forbes, Fukami et al. 2007).  
To date the most effective treatments for diabetic nephropathy target the RAS. Whilst they 
slow down the progression of nephropathy, Clinical studies such as the RENAAL have 
demonstrated that these compounds do not prevent the relentless progression to end stage 
renal disease. 
4.3 The endothelin pathway 
The endothelin pathway has also been shown to be involved in the development and 
progression of diabetic nephropathy.  There are three recognised endothelin proteins: ET-1, 
ET-2 and ET-3, all of which share a high level of homology and have demonstrated 
localisation in a variety of cell types. These vasoactive proteins bind to their receptors ETA, 
ETB, and ETC.  ETA receptors have been shown to induce vasoconstriction and mitogenesis 
whilst ETB receptors has been shown to induce vasoconstriction and vasodilatation (Seo, 
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Oemar et al. 1994; Roux, Breu et al. 1999; Candido and Allen 2002). Importantly, within the 
diabetic kidney, ET-1 has been found to be elevated and altered expression of the receptors 
has also been reported. In addition, modulation of this pathway through the employment of 
ET antagonists has been shown to reduce renal extracellular matrix (ECM) accumulation 
diabetic rats (Jandeleit-Dahm, Allen et al. 2000; Fukami, Cooper et al. 2005). Bosentan, an 
ETA and ETB receptor antagonist has demonstrated renoprotective benefits in the diabetic rat 
which was comparable to enalapril. Currently there are number of clinical trials examining 
the benefits of ET antagonists such as bosentan in diabetic nephropathy.   
5. Modulation of metabolic pathways 
5.1 Glycaemic control  
A range of metabolic abnormalities in addition to hyperglycaemia, are seen in the diabetic 
milieu. However, it is obvious from studies in diabetic patients, that an elevation in 
circulating glucose is the predominant metabolic abnormality and strict glycaemic control, 
remains the ideal therapeutic approach to halt the progression of complications (1998; 2002). 
As well as promoting the formation of AGEs, chronic hyperglycaemia is also associated with 
increased inflammation and expression of associated inflammatory cytokines, such as MCP-
1 (monocyte chemoattractant protein-1) (Dragomir, Tircol et al. 2006), and CTGF (connective 
tissue growth factor) (Makino, Mukoyama et al. 2003), elevated production of ROS (reactive 
oxygen species) and activation of a number of signalling pathways which are involved in 
diabetic nephropathy. At present glycaemic control is achieved through a number of 
approaches including improving insulin sensitivity via agents such as glitazones, increasing 
pancreatic insulin production with sulfonylureas and meglitinides, reducing hepatic glucose 
production with the administration of biguanides, limiting post-prandial glucose absorption 
with ǂ-glucosidase inhibitors (Wagman and Nuss 2001; Fukami, Cooper et al. 2005). 
A novel approach to modulate post-prandial glucose absorption is via targeting glucagon-
like peptide-1 (GLP-1). GLP-1 is an incretin hormone which is known to stimulate insulin 
secretion, increase pro-insulin biosynthesis and improve pacreatic beta-cell viability. 
Recently it has been demonstrated that GLP-1 also posesses a number of extra pancreatic 
functions including anti-apoptotic and anti-inflammatory effects. The actions of GLP-1 are 
also modulated via an endogenous circulating enzyme DPP IV (dipeptidyl peptidase 
inhibitors). At present GLP-1 analogues and inhibitors of DPP-IV are under pre-clinical 
investigation for diabetic nephropathy. Specifically, administration of GLP-1 in an 
experimental model of type-1 diabetes exhibited renoprotective benefits independant of 
glucose control thus warrant further investigation (Kodera, Shikata et al.)  
5.2 Modulation of glucose uptake 
The initial step of glucose signalling it thought to be the translocation of glucose into the 
cells. Glucose uptake into renal cells is facilitated by various glucose transporters 
including SGLT2 (sodium-glucose transporter-2) , GLUT-1(glucose transporter -1) and 
GLUT-4 (glucose transporter-4). Hyperglycaemia is thought to induce an increase in 
expression and /or activity of these receptors which results in elevated intracellular 
glucose, which is one of the fundamental drivers for the development of diabetic 
nephropathy. One of the pathological outcomes of increased glucose transport is 
increased aldose reductase expression and up-regulation of PKC-MAPK (Protein kinase 
C- mitogen activated protein kinase) pathways which lead subsequent elevation in ECM 
(extracellular matrix) proteins such as collagen IV and fibronectin which are pivotal to the 
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development of fibrotic lesions associated with DN (Kanwar, Sun et al.). Moreover, TGF-ǃ 
(Transforming growth factor-ǃ) is known to promote GLUT-1(glucose transporter-1) 
expression and facilitate elevations in intracellular glucose (Fukami, Yamagishi et al. 
2007). Inhibitors of facilitative glucose transporter-2 (SGLT-2) (T-1095), have 
demonstrated potential as therapeutics for diabetic nephropathy in experimental models 
of type 1 diabetes. Administration of T-1095, a synthetic inhibitor of SGLT,  reduced 
plasma glucose and urinary AER and a concomitant decrease in gene expression GLUT-2 
(Fukami, Yamagishi et al. 2007). Thus targeting glucose transporters has exhibited 
renoprotective benefits and further investigation is warranted. 
5.3 Advanced glycation end-products  
AGEs are a heterogeneous and complex group of modifications, which play an important 
role in the development of diabetic nephropathy. They often present as a yellow-brown 
pigmentation, may be fluorescent and a number are primarily cross-links between proteins 
(Brownlee 1992; Brownlee 1995; Kalousova, Zima et al. 2004). AGEs are formed as a result of 
non-enzymatic biochemical reactions initiated as part of the Maillard Reaction. This reaction 
is a multi-step process, where a reactive carbonyl from glucose or its derivatives, are 
attached commonly to lysine and arginine residues on proteins, amino acids and nucleic 
acids (Njoroge and Monnier 1989; Ziyadeh, Cohen et al. 1997). Following further 
condensation, rearrangement and other reactions, the intermediate compounds of which 
some are “Schiff” bases and amadori products, are further irreversibly modified to become 
advanced glycation end products (AGEs) (Njoroge and Monnier 1989; Schrijvers, De Vriese 
et al. 2004). Physiologically, advanced glycation is thought to play an important role in the 
identification of senescent molecules, which are then subsequently cleaved and cleared, 
primarily via the kidneys (Jakus and Rietbrock 2004). 
Within the body, AGEs accumulate from both endogenous and exogenous sources. 
Intracellularly, AGEs are formed as a by-product of a number of important biochemical 
reactions including oxidation of glucose to glyoxal, decomposition of amadori products and 
the fragmentation of glyceraldehydes. The reactive intracellular intermediates formed 
during these reactions, such as methylglyoxal, react with the amino groups of both 
intracellular and extracellular proteins to form AGEs (Brownlee 1992; Bierhaus, Hofmann et 
al. 1998).  
AGEs may be broadly categorised on the basis of their action and function as either non-
cross-linking adducts and cross-linking adducts such as hydroimidazoles (Bohlender, 
Franke et al. 2005). Some of the best characterised AGEs to date, include N-
carboxymethyllysine (CML), N-carboxyethyllysine (CEL), pentosidine, imidazole, 
glyoxallysine dimer (GOLD) and pyrraline (Brownlee 1992; Schrijvers, De Vriese et al. 2004; 
Wolf 2004; Bohlender, Franke et al. 2005). In addition, there are a number of exogenous 
sources of AGEs identified in recent times, including food and tobacco smoke, which also 
contribute to the body’s AGE pool (Cerami, Founds et al. 1997; Koschinsky, He et al. 1997).  
Under normal physiological conditions, AGEs are cleared from the body via the kidney, 
following their degradation by reductase enzymes within cells such as macrophages. The 
kidney via a multi-step process, filters AGE modified-peptides and proteins. Following 
filtration via the glomeruli, they are subsequently reabsorbed by the proximal tubules where 
they are often further degraded and then excreted into the urine (Kalousova, Zima et al. 
2004). In homeostasis, the rate of renal AGE removal is proportional to creatinine clearance, 
ensuring that there is no excess accumulation of tissue AGEs.  
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In metabolic disorders, such as diabetes, there is a marked increase in a number of factors 
which promote the formation and accumulation of AGEs within various susceptible 
organs, in particular, the kidney. As a direct result of the hyperglycaemia characteristic of 
diabetes, there is marked increase in both carbonyl and oxidative stress, which each 
promote in vivo AGE accumulation (Miyata, Haneda et al. 1996; Miyata and van Ypersele 
de Strihou 2003).   
Excessive AGE accumulation can elicit a variety of deleterious effects on tissues and organs. 
These include altering the structure and function of both intracellular and extracellular 
molecules, increasing oxidative stress, modulation of cell activation, enhancement of signal 
transduction pathways and increasing the activation and expression of cytokines and 
growth factors. These actions have been shown to be mediated via both receptor dependant 
and independent mechanisms (Brownlee 1995; Schrijvers, De Vriese et al. 2004 Circulating 
levels of AGEs in diabetic patients are elevated with decreased renal function {Kubba, 2003 
#916). Furthermore, AGE accumulation in tissues correlate with the severity of organ injury, 
particularly within glomerular lesions (Shimoike, Inoguchi et al. 2000; Kanauchi, Nishioka et 
al. 2001).  
Dietary AGEs, are also thought to contribute to the development of diabetic nephropathy. 
Diets low in AGE content, when fed to non-obese diabetic mice (type 1) and db/db mice 
(type 2) reduced glomerular lesions, creatinine/albumin ratios and renal TGF1 expression 
when compared to their high AGE counterparts (Zheng, He et al. 2002). Moreover, diets 
high in AGE content are known to impair insulin sensitivity further confounding 
downstream complications (Hofmann, Dong et al. 2002). Harcourt et al, have recently 
demonstrated the benefits of low AGE diets on kidney function in pre-diabetic, obese 
individuals. Diets low in AGE content elicited improvements in renal function and 
reduction in inflammation (Harcourt, Sourris et al.). Various agents, including LR-90 
(Figarola, Scott et al. 2003), aminoguanidine (Youssef, Nguyen et al. 1999), and ALT-711 
(Forbes, Thallas et al. 2003) are potent in reducing AGE accumulation in renal tissues in 
experimental diabetic nephropathy, subsequently improving renal function. Many other 
agents have elicited similar benefits and have been extensively reviewed previously 
(Alderson, Chachich et al. 2004; Williams and Tuttle 2005; Williams 2006). In addition, 
pyridoxamine, an intermediate of vitamin B6, attenuated the progression of human diabetic 
nephropathy and concurrently reduced AGE and urinary TGF-ǃ(Williams, Bolton et al. 
2007). Furthermore, benfotiamine (liposoluble vitamin B1 derivative), decreases AGE 
accumulation, inflammation and improves vascular function in type 2 diabetic patients 
consuming diets high in AGE content (Stirban, Negrean et al. 2006). To date there have been 
three clinical trials conducted which employed AGE-lowering therapies . Aminoguanidine 
and benfotiamine trials were stopped due to toxicity of the therapy. The third trial 
employed Alagaebrium in type 1 diabetic patients in addition to an ACE-inhibitor. This trial 
has now ended and results are pending.   
5.4 AGE-receptors  
The receptors for AGE are important modulators of the deleterious effects of these 
compounds. Receptors for AGEs may be loosely grouped as either inflammatory (RAGE, 
AGE-R2) or clearance type receptors (AGE-R1, AGE-R3, CD36, Scr-II, FEEL-1 and FEEL-2) 
(Vlassara and Bucala 1996; Vlassara 1997; Singh, Barden et al. 2001; Forbes, Yee et al. 2004; 
Schrijvers, De Vriese et al. 2004; Alikhani, Alikhani et al. 2005). Vascular, renal, neuronal and 
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haematopoietic cells are all known to express receptors for AGEs (Goldin, Beckman et al. 
2006; Sourris and Forbes 2009) AGEs contribute to the pathogenesis of diabetic nephropathy 
via receptor mediated mechanisms and indirectly via the generation of reactive oxygen 
species and by altering extracellular matrix (ECM) integrity.  
Diabetes alters the expression of a number of AGE-receptors thought to drive the 
development and progression of diabetic nephropathy, in particular, the expression of 
RAGE on cells such as podocytes and tubular epithelial cells (Soulis, Thallas et al. 1997; 
Wendt, Tanji et al. 2003; Gu, Hagiwara et al. 2006; Li, Nakamura et al. 2006).  
Another AGE receptor postulated to be involved in the development of diabetic 
nephropathy is AGE-R1, although converse to RAGE this is likely via a decrease in 
expression. In an experimental model of type 1 diabetes, renal AGE-R1 expression is 
reduced in association with a concurrent increase in AGE deposition and progression to 
diabetic nephropathy (He, Zheng et al. 2000; Vlassara 2001). In addition, we recently 
reported that in a small cohort of type 2 diabetic patients we found a positive correlation 
with AGE-R1 expression on the cell surface of peripheral blood mononuclear cells and renal 
function. We found that this was the most predictive biomarker for renal function and 
further investigation in a larger cohort is required {Sourris, #9145}.  
The contribution of AGE-R3 to the development and progression of diabetic nephropathy 
has not been extensively researched. However, AGE-induced increases in the expression of 
AGE-R3 has been demonstrated in cultured endothelial cells and within renal tissues in the 
diabetic milieu (Iacobini, Oddi et al. 2005; Kumar, Narang et al. 2006). This however, may 
indicate a protective role for AGE-R3 given that AGE-R3 deficient mice develop more severe 
renal disease and have marked increases in renal AGE deposition (Iacobini, Oddi et al. 
2005). Furthermore, AGE-R3 deficient mice develop albuminuria, mesangial expansion and 
fibrosis within the kidney cortex which is more pronounced with diabetes. Importantly, the 
deletion of AGE-R3 was also associated with a decrease in AGE-R1 and increased 
expression of RAGE demonstrating the existence of AGE-receptor cross talk. This study 
highlights that the role of AGE-R3 in the clearance of AGEs (Pugliese, Pricci et al. 2000) is 
likely more important in diabetic nephropathy than its ability to modulate immune 
function. The modulation of AGEs and their receptors have been extensively reviewed 
previously (Sourris and Forbes 2009). 
6. Hyperlipidaemia 
Hyperlipidaemia is a comorbidity often seen in diabetic patients and is thought to be an 
important contributor to progressive micro and macrovascular complications. This is most 
clearly demonstrated by the renoprotection which is seemingly afforded with HMG CoA 
reductase inhibitors (Tonolo, Ciccarese et al. 1997; Fujii, Inoguchi et al. 2007; Matsumoto, 
Tanimoto et al. 2008). Obesity is one the leading factors which drive the development of 
type 2 diabetes and its complications such as nephropathy. Moreover, it has also been 
shown to lead to kidney disease in the absence of diabetes. As one of the leading causes of 
chronic kidney disease, the WHO has recommended that lifestyle changes such as dietary 
and exercise are the most cost-effective approaches to combating this epidemic. We have 
recently reported the benefits of dietary intervention and renal function in a obese, non-
diabetic population (Harcourt, Sourris et al.). 
www.intechopen.com
 
Diseases of Renal Parenchyma 
 
186 
7. Reactive oxygen species 
Reactive oxygen species are important intermediates in the formation of AGEs and are often 
excessively generated in the kidney in diabetes (Forbes, Coughlan et al. 2008). In addition, 
concomitant dysregulation of anti-oxidant enzymes in diabetes, leads to a state of oxidative 
stress (Forbes, Coughlan et al. 2008). To date, it is unclear as to why exogenous 
administration of antioxidants per se has demonstrated such poor renoprotection in humans, 
despite exciting positive preclinical research findings. However, it seems evident that 
therapies such as vitamins may not be the ideal antioxidant strategy in human DN. Vitamin 
B6 derivatives (Hammes, Du et al. 2003; Endo, Nishiyama et al. 2007), metformin (Rahbar, 
Natarajan et al. 2000), OPB-9195 (Wada, Nishizawa et al. 2001; Mizutani, Ikeda et al. 2002), 
ACEi (Miyata, van Ypersele de Strihou et al. 2002; Coughlan, Thallas-Bonke et al. 2007), AT1 
antagonists (Miyata, van Ypersele de Strihou et al. 2002), ALA (Coughlan, Thallas-Bonke et 
al. 2007) and sRAGE (Wautier, Zoukourian et al. 1996) have exhibited beneficial effects on 
excess superoxide generation within tissues, associated with improvements in the 
development and/or progression of diabetic complications.  
Vitamin B-related therapeutics are effective scavengers of ROS intermediates. Pyridoxamine, 
inhibits superoxide radical generation, as well as preventing the progression of neuropathy 
and retinopathy (Jain and Lim 2001). In addition benfotiamine and thiamine, Vitamin B1 
derivatives, have shown beneficial effects in normalising ROS production and reducing the 
activity of aldose reductase (Berrone, Beltramo et al. 2006). Paradoxically, thiamine 
administered to human with diabetic renal disease actually worsened renal function 
(Rabbani, Alam et al. 2009). The role of ROS in diabetic kidney disease has been extensively 
reviewed previously (Forbes, Coughlan et al. 2008).  
8. Inhibition of protein kinase C (PKC) activity  
There has been a growing body of evidence suggesting the central role of PKC, which is 
broadly involved in signal transduction from the plasma membrane to the nucleus, in 
diabetes induced vascular dysfunction (Inoguchi, Battan et al. 1992; Xia, Inoguchi et al. 
1994). PKC has 11 different isoforms, many of which have been shown to be involved in 
diabetic complications, in particular nephropathy. (Koya, Jirousek et al. 1997; Koya, Haneda 
et al. 2000; Meier, Park et al. 2003).  Of the 11 isoforms, PKC-ǂ, -ǃ, -ǅ, -ǆ, -ξ are expressed 
within the kidney (Kanwar, Sun et al.) PKC pathway is known to be activated by many 
factors including:  Elevations in diacylglycerol, hydrogen peroxide, increased activity of 
polyol pathway, mitochondrial superoxide activity (Geraldes and King) and following AGE-
RAGE interactions (Kanwar, Sun et al.). PKC isoforms have been associated with many 
cellular and vascular alterations and processes including: endothelial dysfunction, 
angiogenesis, vascular permeability, cell growth and apoptosis, basement membrane 
thickening, extracellular matrix (ECM) expansion. PKC pathway is known to be activation 
of numerous cellular pathways including NADH, ROS, Na+/K+ ATPase , Endothelin (ET-1), 
Ang II, MAPK and phospolipase A2 and VEGF (Geraldes and King; Kanwar, Sun et al.).  
We have recently reported the attenuation of PKC-ǂ phosphorylation and translocation with 
ALA in both in vivo models of DN and in vitro studies (Thallas-Bonke, Lindschau et al. 2004).  
It remains to be determined if this action of alagebrium on PKCǂ phosphorylation partly 
explains its renoprotective actions. Modulation of PKC activity within the diabetic kidney 
has also been exhibited by various vitamin B derivatives (Babaei-Jadidi, Karachalias et al. 
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2003; Hammes, Du et al. 2003). Interestingly, both ACEi and aminoguanidine prevent 
diabetes associated increases in PKC  activation in renal glomeruli (Osicka, Yu et al. 2000).  
The effects of aminoguanidine and ACEi on PKC  activity were also observed at other sites 
of vascular injury including the retina and mesenteric vascular bed (Osicka, Kiriazis et al. 
2001; Miyata, van Ypersele de Strihou et al. 2002). In addition, AT-1 receptor antagonists, 
also attenuate diabetes induced increases in PKC -epsilon activity within the diabetic heart 
(Malhotra, Reich et al. 1997). Furthermore, modulation of PKC has been demonstrated in 
vascular endothelial cells with the insulin sensitizing agent metformin (Isoda, Young et al. 
2006) and the anti-thrombotic therapeutic, aspirin (Dragomir, Manduteanu et al. 2004). We 
have demonstrated that in our experimental models of diabetes translocation of PKC ǂ to 
the membrane is associated with parallel increases in superoxide production and elevated 
urinary VEGF thus highlighting the importance of this pathway in DN. In the clinical 
setting, roboxistaurin, is a PKC inhibitor which Tuttle et al, demonstrated that 32mg/day in 
addition to an ACEi for 12 months reduced urinary ACR (Geraldes and King). Moreover, 
renal biopsies from diabetic patients exhibited almost 10-fold increase in PKC  gene 
expression compared to their control (Geraldes and King; Langham, Kelly et al. 2008).  In 
addition, the importance of PCK isoforms has been demonstrated in experimental models of 
diabetic nephropathy. PCK-ǂ and ǃ knockout mice exhibited a high level of resistance to the 
development of diabetic renal disease (Meier, Park et al. 2007; Meier, Menne et al. 2009; 
Tossidou, Starker et al. 2009).  
9. Nuclear transcription factor kappa-B (NF-B) 
NF-B is a transcription factor composed of two subunits, the most common of which are 
the p50 and p65 subunits (Barnes and Larin 1997) which are thought to be important 
modulators of diabetic complications. The active p65 subunit in particular, is thought to be 
central in the activation of numerous genes including cytokines, adhesion molecules, NO 
synthase, angiotensinogen and many other inflammatory and proliferative proteins 
implicated in the process of diabetic nephropathy (Barnes and Larin 1997; Bierhaus, 
Schiekofer et al. 2001). NF-B is activated by a range of stimuli including glucose (Pieper 
and Riazulhaq 1997) and ROS (Nishikawa, Edelstein et al. 2000). AGEs are also involved in 
activation of NF-B via a RAGE-dependent pathway leading to its translocation to the 
nucleus where it induces transcription of target genes such as IL-6 and TNF-ǂ (Yan, Schmidt 
et al. 1994). The diverse actions of NF-κB and the capacity of various factors such as AII and 
AGEs to activate this transcription factor (Ruiz-Ortega, Lorenzo et al. 2000; Ruiz-Ortega, 
Lorenzo et al. 2000), are consistent with NF-B playing a pivotal role in the pathogenesis of 
diabetic complications. 
Pyrrolidine dithiocarbamate (PDTC) is a NF-B inhibitor which has been used in both 
diabetic (Lee, Cao et al. 2004) and non-diabetic animal models of renal disease where it is 
renoprotective (Rangan, Wang et al. 1999), although its toxicity does not allow for direct 
translation to the clinical setting. Indeed, our group has demonstrated the importance of NF-
B in the pathogenesis of early renal macrophage infiltration in experimental diabetes, 
which could be modulated by interruption of the RAS (Lee, Cao et al. 2004; Liu, Wei et al. 
2006). Moreover, diabetes-induced increases in NF-B activation are prevented by 
numerous therapeutics including Metformin (Isoda, Young et al. 2006) aspirin (Zheng, 
Howell et al. 2007) Vitamin B derivatives (Hammes, Du et al. 2003) carnosine (Odashima, 
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Otaka et al. 2006) and thiazolidinediones (Marx, Walcher et al. 2004). It is possible that NF-
B, like PKC, is a central mediator which drives the downstream pathogenic consequences 
of interactions between hemodynamic and glucose dependent pathways in diabetic vascular 
complications. However, approaches to inhibit NF-B have not been explored fully in DN, 
most likely due to the intimate involvement of this transcription factor in a number of 
essential cellular processes including apoptosis.  
10. Inflammatory cytokines and growth factors 
Diabetic nephropathy was not traditionally considered to be an inflammatory condition, 
however, there is a growing body of evidence in recent times highlighting the central role of 
inflammation in its development and progression (Wu, Huang et al. 2002; Forbes, Cooper et 
al. 2003; Chow, Ozols et al. 2004; Chow, Nikolic-Paterson et al. 2004; Chow, Nikolic-Paterson 
et al. 2006; Nguyen, Ping et al. 2006; Chow, Nikolic-Paterson et al. 2007; Ninichuk, 
Khandoga et al. 2007; Giunti, Tesch et al. 2008; Hohenstein, Hugo et al. 2008). Indeed,  
both hemodynamic and metabolic factors involved in the development of diabetic 
complications such as nephropathy activate common downstream targets, including 
cytokines and growth factors (Cooper, Gilbert et al. 1998). In particular, Monocyte 
Chemoattractant Protein (MCP-1), Transforming Growth Factor-ǃ1 (TGF-1), Connective 
Tissue Growth Factor (cTGF) and Vascular Endothelial Growth Factor (VEGF) have all been 
implicated in both experimental and human studies to be involved in the development and 
progression of diabetic nephropathy.  
10.1 Monoctye chemoattractant protein -1 (MCP-1) 
MCP-1 is a potent chemokine which encourages monocyte/macrophage infiltration into the 
kidney, which likely contributes to the progression of DN. MCP-1 production and secretion 
from damaged renal cells in diabetes are postulated to be a response to hyperglycaemia 
subsequently activating a number of signalling pathways including those mediated by PKC 
and NF-B (Tesch 2008). In an experimental model of type 2 diabetic nephropathy, a 
deficiency in MCP-1 resulted in a significant reduction in renal inflammatory infiltration and 
renoprotection, Furthermore administration of propagermanium, an antagonist of the MCP-1 
receptor, in model of diabetic nephropathy, resulted in reduced renal hypertrophy and 
macrophage infiltration in renal glomeruli (Kanamori, Matsubara et al. 2007). Indeed, it has 
been demonstrated that elevations in urinary excretion of MCP-1 may be a valid diagnostic 
marker of diabetic nephropathy in type 2 diabetic patients (Wang and Chen 2009). These 
studies suggest that MCP-1 is a central mediator of diabetic renal disease, although its utility 
as a therapeutic target remains to be determined (Chow, Nikolic-Paterson et al. 2007).  
10.2 Modulation of growth factors 
Growth factors such as transforming growth factor-ǃ (TGF-ǃ), a fibrogenic cytokine, and 
connective tissue growth factor (CTGF), which is primarily induced by TGF- ǃ1, have been 
implicated as key effector molecules which promote diabetic renal disease. Transforming 
growth factor beta is a superfamily with three mammalian isoforms. The major isoform, 
TGF-1 is synthesised as an inactive or latent form, which subsequently is subjected to 
proteolytic cleavage leading to the generation of the active form. TGF-1 binds to the type II 
receptor and subsequently binds to the type I receptor (Wrana, Attisano et al. 1994) inducing 
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phosphorylation and intracellular signalling involving the SMAD proteins (Massague 1998). 
In vitro studies have shown that a range of stimuli increase TGF-1 expression including 
hyperglycaemia, AGEs, stretch, AII, endothelin, lipids and various products of oxidative 
stress such as F2 isoprostanes, all factors relevant to DN (Rocco, Neilson et al. 1992; Wolf, 
Ziyadeh et al. 1995; Herman, Emancipator et al. 1998; Gruden, Thomas et al. 1999; Jandeleit-
Dahm, Cao et al. 1999; Montero, Munger et al. 2000). Ziyadeh et al have previously 
examined the effects of long-term administration of a neutralizing TGF-ǃ1 antibody on renal 
function and structure in diabetic db/db mice (Ziyadeh, Hoffman et al. 2000) and STZ 
diabetic mice (Sharma, Jin et al. 1996). Although most of the benefits have been attributed to 
TGF-ǃ1, Hill et al. have suggested that another isoform, TGF-ǃ2, is closely linked to 
fibrogenesis in diabetic nephropathy (Hill, Flyvbjerg et al. 2000). The utility of TGF-ǃ1 as a 
target for therapeutic intervention in DN, however, is impeded by its essential role in 
inflammatory and immune processes. Therefore it may be preferable to modulate renal 
TGF-ǃ1 levels by an alternative approach such as therapies which focus on upstream 
advanced glycation pathways.  A clinical trial in type 2 diabetic patients has recently ended 
and reports have been released. In this study by Sharma et al, they employed the anti-
fibrotic therapeutic, Pirfenidone at two different doses to investigate the benefits on renal 
function. Administration of Perfenidone at the lower dose of 1200mg resulted in a 
concurrent improvement in renal function and reduction in TGF-ǃ thus demonstrating its 
benefits as a potential therapeutic for diabetic nephropathy (Sharma, Ix et al.). 
10.3 Connective tissue growth factor 
Another pro-sclerotic cytokine, connective tissue growth factor (CTGF) has increased renal 
(Riser, Denichilo et al. 2000; Twigg, Cao et al. 2002) and in particular, glomerular expression 
in diabetes (Murphy, Godson et al. 1999; Riser, Denichilo et al. 2000) and elevated in both 
early and late diabetic nephropathy in humans (Ito, Aten et al. 1998). Currently a Phase II 
study of FG-3019, a humanised anti-CTGF antibody, has been completed in patients with 
diabetic nephropathy (microalbuminuria) which was well tolerated and improved 
albuminuria. Subsequent, studies are planned in diabetic patients with macroalbuminuria 
(http://www.fibrogen.com/trials).  
CTGF expression is thought to be mediated by a number of factors common in diabetic 
nephropathy including TGF-1, hyperglycaemia or mechanical stretch (Riser, Denichilo et 
al. 2000). Interestingly, AGEs have been reported to specifically increase CTGF expression, 
initially in fibroblasts (Twigg, Chen et al. 2001) but subsequently in mesangial cells (Twigg, 
Chen et al. 2001). Moreover, aspirin has also been shown to prevent the diabetes-mediated 
increase in CTGF and mesangial expansion in experimental models of DN (Makino, 
Mukoyama et al. 2003).  
10.4 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a cytokine whose major role in diabetes was 
initially considered to be central for the pathogenesis of diabetic retinopathy and in 
particular retinal neovascularisation. Recent findings, however, have demonstrated the 
importance of VEGF within the diabetic kidney (De Vriese, Tilton et al. 2001; Wada, 
Nishizawa et al. 2001; Rizkalla, Forbes et al. 2003; Wendt, Tanji et al. 2003; Thallas-Bonke, 
Lindschau et al. 2004)]. We and others have previously shown both in vivo and in vitro 
decreases in VEGF expression with a number of therapies including alagebrium (Thallas-
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Bonke, Lindschau et al. 2004), ACE inhibitors (Thallas-Bonke, Lindschau et al. 2004), sRAGE 
(Wendt, Tanji et al. 2003) and OPB-9195 (Wada, Nishizawa et al. 2001). Despite this 
suppression of VEGF as a result of current therapeutics, the benefits of VEGF suppression 
remain controversial with some studies suggesting that VEGF blockade is renoprotective 
(De Vriese, Tilton et al. 2001), whereas recent studies, albeit in a non-diabetic context, 
suggest that VEGF is a critical renal survival factor and that blockade may in fact promote 
renal damage (Advani, Kelly et al. 2007). This is perhaps best demonstrated by the 
differential effects seen with anti-VEGF antibodies (192,193). Studies on the renal effects of 
blockade of VEGF receptor (VEGFR) signalling are currently being performed. Indeed, a 
recent preliminary report has shown that SU5416, a VEGFR tyrosine kinase inhibitor, 
reduces albuminuria in db/db mice (Sung 2004). In experimental models of DN, VEGF 
expression is also decreased by an inhibitor of AGE formation (Tsuchida, Makita et al. 1999) 
and with the AGE cross-link breaker, ALA (Thallas-Bonke, Lindschau et al. 2004) further 
confirming the link between AGEs and VEGF expression. 
11. Targeting genetic mediators of diabetic nephropathy 
Whilst, genetic factors and gene mutations have been implicated in the development and 
pathogenesis of diabetes for some time, recent evidence has implicated the involvement of , 
microRNA’s, histone methylation and metabolic memory in diabetes and specifically its 
complications. 
11.1 MicroRNAs (miRNAs) 
MiRNAs are regulatory RNAs that act as post-transcriptional repressors by binding to the 
3’untranslated region of target genes (Akkina and Becker; Guay, Roggli et al.). The 
mammalian genome encodes for several hundred miRNAs, and within the kidney, the 
miRNA profile differs from that of other tissues and indeed within different compartments 
of the kidney (Akkina and Becker; Guay, Roggli et al.). Initially miRNAs are transcribed as 
long pre-miRNA molecules which are subsequently modified to become their mature 
miRNA form, approximately 19-25 nucleotides in length, via a number of different 
processes. A strand of mature miRNA enters the RNA-inducing silencing complex (RISC) 
where it binds to the 3’ untranslated region of its target mRNA thus resulting in reduced 
expression of the targeted gene (Akkina and Becker) The miRNA which are in greatest 
abundance within the kidney include: miR-192, 194, 204, 215 and 216. Kantharidis et al have 
demonstrated in-vitro and ex-vivo potential of miRNA as therapeutic targets in diabetic 
nephropathy.  Specifically, they have demonstrated the role of microRNA’s in the fibrosis 
associated with diabetic nephropathy.  MicroRNA-192/215 was found to regulate the pro-
fibrotic protein e-cadherin whilst miRNA-200a was found to repress the expression of TGF-
ß2 (Wang, Herman-Edelstein et al.; Wang, Koh et al.)  Natarajan et al have alos extensively 
investigated microRNA in diabetic renal disease in experimental models (Kato, Arce et al.; 
Kato, Arce et al. 2009; Kato and Natarajan 2009; Kato, Putta et al. 2009). This therefore 
highlights the potential of microRNA’s as therapeutic targets for diabetic nephropathy and 
further pre-clinical work is warranted.  
11.2 Metabolic memory 
A number of pre-clinical and clinical trials have implicated the involvement of metabolic 
memory and the development of diabetic complications. Metabolic memory refers to an 
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earlier hyperglycaemic or erratic metabolic controlled state which is then followed by 
“normoglycaemia” or good glycaemia control.  This phenomenon is poorly understood, 
however it suggests that despite improved glycemic control, the original exposure to 
hyperglycaemia is enough to sustain prolonged deleterious effects and outcomes.  Metabolic 
memory has been demonstrated in both experimental and cell culture models of diabetes. In 
addition, numerous clinical trials, including the United Kingdom Prospective Diabetes 
Study (UKPDS) and The Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) demonstrated that intensive 
glycaemia control may help decrease micro and macrovasuclar complications thus 
suggesting the existence of metabolic memory (Villeneuve and Natarajan). Brassacchio et al 
have demonstrated the existence of “hyperglycaemic memory” in an in-vitro model of 
diabetes (Brasacchio, Okabe et al. 2009) however further investigation into this phenomenon 
is warranted and would undoubtedly reduce the onset and progression of diabetic 
complications, including nephropathy.  
11.3 Histone modifications 
Post-translational modifications that occur at the histone tails including: acetylation, 
methylation, and phosphorylation, one of the many methods through which regulation  
of gene transcription is achieved. Traditionally, post-translational modifications, such  
as DNA methylation have been extensively studied in the area of cancer. Recent reports 
have demonstrated the importance of histone modifications in diabetic complications.  
Pre-clinical studies in white blood cells including monocytes from diabetic patients  
have exhibited epigenetic modifications including increases in H3K9me2 AND H3K4me2 
which are associated with immune and inflammatory pathways (Villeneuve and Natarajan).  
In addition, TGF- ß treatment of renal mesangial cells were found to induce an increase  
in HMT SET7/9 which was associated with a profibrotic phenotype (Villeneuve and 
Natarajan). Histone modifications therefore demonstrate great potential as therapeutic 
targets.  
12. Clinical trials: The current state of affairs 
It is clearly evident that there is an abundance of potential therapeutic targets for the 
treatment of diabetic nephropathy. So why are we failing to translate these into positive 
outcomes in patients? We investigated the NIH database for clinical trials (completed and 
running) which targeted diabetic nephropathy. Of the 200 trials listed in the database, we 
categorised the interventions into their broad subject groups (Table 1). Our search found 
that 35% of all trials, employed interventional therapies which targeted the renin-
aldosterone-angiotensin system, which to date have proven to be the most beneficial 
therapeutic approach (Table 1). Approximately 13.5% of all clinical trials were investigating 
therapies which target glycaemic control (including insulin). Dietary intervention is a more 
cost effective therapeutic approach for the treatment of diabetic nephropathy constituted 
some 20% of all clinical trials registered within the NIH data base. It is evident that the 
wider research community is actively investigating novel therapeutic targets other than 
those which target the RAAS, demonstrated by the variety of interventions and categories. 
Of particular interest, is that of all of these trials, almost 10% of these targeted ROS whilst 
5% employed anti-inflammatories. In addition, 1.5% of all trials targeted AGEs and/or their 
receptors (Table 1). The remainder of the trials targeted thrombosis, fibrosis, erythropoiesis, 
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heparin, PKC, calcium transport, endothelin and genetics (Table 1). A recent search into the 
diabetic nephropathy patent database has identified that other new novel therapeutics 
including vasohibin ( 20100113354), myostatin (20110008357), Oligotide ( 20100291098), 
modulators of prostacyclin (20110053872), inhibitors of galectin-3 (20080219973) and 
inhibitors of fatty acid oxidation ( 20110048980) are being considered for the treatment of 
diabetic renal disease. Moreover, novel biomarkers for the development and progression of 
diabetic nephropathy are also under investigation including urinary: precursor ǂ-2-HS-
glycoprotein, ǂ-1-antitrypsin, ǂ-1-acid glycoprotein and osteopontin.  
 
TARGET PERCENTAGE 
Glycaemic Control 
(including insulin and glucose transport ) 
14.5% 
Advanced Glycation End-Products 1.5% 
Reactive Oxygen Species 9% 
Inflammation 5% 
Renin-aldosterone-angiotensin system 35% 
Endothelin 2.5% 
Dietary Interventions 17.5% 
Pro-fibrotic molecules 2% 
Anti-Thrombotic 1.5% 
Genetics 1% 
Protein Kinase C- inhibitors 1% 
Anti-Lipidaemic 4.5% 
Calcium Blockers 1.5% 
Others – diuretics, hormones, apoptosis, 5% 
Table 1. Therapeutics in clinical trials for treatment of diabetic nephropathy Representative 
table of Clinical Trials run to treat diabetic nephropathy and registered on NIH webpage. 
13. Conclusion  
Diabetic nephropathy is a multifaceted disease which encompasses hemodynamic, 
metabolic and genetic factors which are central to its development and progression. At 
present therapeutics which target the hemodynamic factors, specifically the renin-
aldosterone-angiotensin system are the most effective treatments. Unfortunately, their 
benefits are limited and as such additional novel therapeutics are required. In this chapter 
we have described an number of potential therapeutic targets which have been identified 
and which are either in clinical or pre-clinical investigation. In the future, it is hoped that 
current clinical trials will show benefits of some of these novel agents and that there will be 
significant advanced in our management of individuals with diabetic renal disease.  
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